Tinuviel Therapeutics is Selected for the Wellcome Leap FORM Program

Tinuviel Therapeutics is proud to contribute to Wellcome Leap’s Foundations of a Resilient Microbiome (FORM) program, a global program bringing together leading researchers, clinicians, engineers and technology innovators to accelerate breakthroughs in our understanding of microbiome resilience in early life and its role in human neurodevelopment. Through FORM, Tinuviel is developing a first-of-its-kind human microbiome digital twin platform that enables the measurement, prediction, and engineering of microbiome resilience in early life, with the potential to power next-generation screening, diagnostics and precision microbiome therapeutics to build developmental resilience early in life.